Is a complete NSRX research report available?

No complete published report is available for Nasus Pharma Ltd. (NSRX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Nasus Pharma Ltd. (NSRX)

NYSEAMERICAN: NSRX · USD

$3.12

+0.03 (+0.9%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-27 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first NSRX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	36.5M
Net income (ttm)	-5.9M
EPS (ttm)	-$0.73
Shares out	11.7M
Volume	37,209.652
Price target	$19.7	+530.4%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -5.9M
EPS (ttm): -$0.73
Market cap: 36.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All NSRX indicators

Market & fundamental data

Available fields

155

Groups with data

Currency

USD

Showing 155 of 155 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002029039
Company name	Nasus Pharma Ltd.
Country	Israel
Country code	US
Cusip	64126Y307
Employees	7
Employees Change	5%
Employees Change Percent	250
Enterprise value	$32.4M
Exchange	NYSEAMERICAN
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - General
Industry PE	27.46
Industry PE Fwd	19.21
IPO Date	2025-08-14
Isin	IL0012181553
Last refreshed	2026-07-27
Market cap	$36.5M
Market cap category	Nano-Cap
Price	$3.12
Price currency	USD
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2834
Symbol	NSRX
Website	https://www.nasuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-16.03%
FCF yield	-13.5%
P/B ratio	10.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-5.9M
Net Income Growth Years	0%
Profit Per Employee	$-836,571
ROA	-107.1
ROCE	-172.6
ROIC	-415.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$5M
Cash	$4.3M
Current Assets	$4.9M
Current Liabilities	$2.2M
Debt	$118,000
Debt Equity	$0.04
Equity	$2.8M
Liabilities	$2.2M
Long Term Assets	$149,000
Long Term Liabilities	$73,000
Net Cash	$4.2M
Net Cash By Market Cap	$11.41
Net Debt Equity	$-1.51
Tangible Book Value	$2.8M
Tangible Book Value Per Share	$0.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.24
Net Working Capital	$-1.5M
Quick ratio	1.98
Working Capital	$2.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-15.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
200-day SMA	4.99
50-day SMA	3.09
50-day SMA vs 200-day SMA	50under200
All Time High	9.99
All Time High Change	-68.77%
All Time High Date	2025-08-22
All Time Low	1.98
All Time Low Change	57.58%
All Time Low Date	2026-03-31
ATR	0.21
Beta1y	1.18
Ch YTD	-65.9
High	3.15
High52	9.99
High52 Date	2025-08-22
High52ch	-68.77%
Low	2.92
Low52	1.98
Low52 Date	2026-03-31
Low52ch	57.58%
Ma50ch	0.84%
Price vs 200-day SMA	-37.47%
RSI	50.58
RSI Monthly	0
RSI Weekly	39.84
Sharpe ratio	-0.51x
Sortino ratio	-0.65
Tr YTD	-65.9
Tr1m	-5.45%
Tr1w	3.65%
Tr3m	-8.24%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.19
Operating Income	$-4.9M
Price target	$19.67
Price Target Change	$530

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4,856,096%
Float Percent	41.47%
Shares Insiders	34.25%
Shares Institutions	10.66%
Shares Out	11,710,808
Shares Yo Y	15.11%
Short Float	3.51%
Short Ratio	7.9
Short Shares	1.46

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-5.4M
Average Volume	14,333.95x
Bv Per Share	0.31
CAPEX	$-14,000
Ch1m	-5.45
Ch1w	3.65
Ch3m	-8.24
Ch6m	-50.08
Change	0.87%
Change From Open	6.85
Close	3.09
Days Gap	-5.59
Dollar Volume	116,094.1
Earnings Date	2026-03-25
Earnings Time	bmo
EBIT	$-4.9M
EBITDA	$-4.9M
EPS	$-0.73
F Score	2
FCF	$-4.9M
FCF EV Yield	-15.24x
FCF Per Share	$-0.42
Financing CF	8,920,000
Fiscal Year End	December
Founded	2,019
Investing CF	-3,014,000
Ipr	-61
Iprfo	-64.55
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-25
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-25
Ma150	4.18
Ma150ch	-25.32%
Ma20	3.17
Ma20ch	-1.45%
Net CF	980,000
Next Earnings Date	2026-12-29
Open	2.92
Optionable	No
Position In Range	86.96
Ppne	149,000
Price Date	2026-07-24
Ptbv Ratio	13.2
Relative Volume	2.6x
Share Based Comp	447,000
Tr6m	-50.08%
Volume	37,209.7

Nasus Pharma Ltd. (NSRX)

Coverage state: Market snapshot only — no published research

Generate the first NSRX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · NSRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NSRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on NSRX

Frequently asked questions